Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > No one wants xb3
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(40)
•••
Post by zwerp2000on Feb 04, 2023 11:02am
297 Views
Post# 35266719

No one wants xb3

No one wants xb3Stop fooling yourselves. The company has done nothing for years and years. Other companies have evaluated xb3 and passed. If there was any utility to xb3, someone would have made a play. No one did. The company tried to unload it for nothing to MTP in a last ditch attempt which not only voted  against the acquisition but now we find out the company is pretty much bankrupt. It is ridiculous that some of you think xb3 has enormous value and there is some sort of consipiracy to steal this from shareholders. xb3 is junk. No one wants it. Pretty soon BTI will default on it's debt obligations. The ceo will announce they tried to save the company with MTP but that having failed, the company has no other alternatives but to wind down operations. 
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities